红杉中国刚刚收购拜耳集团重要资产

Core Viewpoint - Bayer AG has agreed to sell its antibiotic drug Avelox to Sequoia China for an estimated transaction value between €160 million and €260 million, reflecting the growing investment value in off-patent branded drugs in China [1][2]. Group 1: Transaction Details - The sale includes Avelox's intellectual property, brand ownership, and global commercial rights [1]. - HSBC acted as the exclusive financial advisor for Bayer, while Shanghai Pudong Development Bank provided loan financing support to Sequoia China [1]. Group 2: Market Context - Avelox, a broad-spectrum antibiotic, was approved by the FDA in 1999 and peaked in sales in 2012, but has seen a decline since then [1]. - In 2021, Avelox's global sales were reported at $72 million, with Bayer's original brand holding a 40% market share in China despite competition from 22 local generic manufacturers [2]. Group 3: Industry Trends - The transaction highlights the investment opportunities in the market for off-patent branded drugs, as multinational pharmaceutical companies focus on innovative drug pipelines [2]. - The period from 2025 to 2029 is expected to see a new wave of patent expirations, with an estimated annual sales value of $180 billion for expiring drugs [3]. - Chinese capital is becoming a key player in the transaction of expired patent drug assets, as exemplified by Sequoia China's acquisition of Avelox [3].